Exerkines: The Signals Exercising Muscle Sends Around the Body
When a muscle works, it does not only burn fuel. It also releases chemical messages into the blood, and other organs — fat, liver, bone and brain — respond to them. Scientists call these messages exerkines (exercise signals), and the ones that come from muscle itself myokines. The idea explains part of why exercise seems to help so many organs at once, and it has produced some famous molecules: interleukin-6, irisin, beta-aminoisobutyric acid, lactate, fibroblast growth factor 21, apelin, meteorin-like and osteocalcin. This page goes through each one and separates what was measured in people from what was found in mice or in cells, because the two often tell different stories. It also covers whether any of these signals can be taken as a pill, and what is still not known.
For the broad evidence on exercise itself — how much, and what it does for the heart, metabolism, mood and ageing — see the main Exercise page. One of the signals below has its own full page: BAIBA (beta-aminoisobutyric acid).
Table of Contents
- Exerkines Are Messages Released by Exercise
- Interleukin-6 Was the First Signal Traced to Working Human Muscle
- Irisin Became Famous Before It Could Be Measured
- Beta-Aminoisobutyric Acid Rises a Little in People and Acts Strongly in Mice
- Lactate Is a Fuel and a Signal, Not Just Waste
- Fibroblast Growth Factor 21 Comes From the Liver
- Apelin, Meteorin-Like and Osteocalcin Are Newer Candidates
- What the Records Report for Blood Sugar, Fat, Bone and Brain
- Most Findings Come From Mice, and Human Data Often Differ
- Exerkines as Pills: What Trials Have Tested
- What Is Not Known
- Key Research Papers
- Connections
- Featured Videos
Exerkines Are Messages Released by Exercise
A 2022 review by a large group of exercise scientists defines exerkines as signalling molecules released in response to a single bout of exercise, to regular training, or to both. They act on distant organs (like a hormone), on nearby cells, or on the same cell that made them. The same review notes that many tissues release them, and gives each group a name:
- Myokines — from skeletal muscle.
- Cardiokines — from the heart.
- Hepatokines — from the liver.
- Adipokines — from white fat.
- Baptokines — from brown fat.
- Neurokines — from nerve cells.
The review dates the field to the discovery in 2000 that contracting muscle releases interleukin-6, and says that since then the number of known exercise-linked signalling molecules has multiplied. It describes their possible roles in heart, metabolic, immune and brain health, and their potential for treating cardiovascular disease, type 2 diabetes and obesity. In the same breath it states that the molecular mechanisms behind the benefits of exercise “remain poorly understood”.
Two points help when reading claims about any single exerkine:
- “Myokine” is used loosely. Strictly, a myokine is a protein made by muscle. Some of the molecules below are small metabolites (lactate, beta-aminoisobutyric acid), and one of the best-studied “exercise hormones”, fibroblast growth factor 21, turns out to come mainly from the liver.
- A rise in the blood is not proof of an effect. Exercise changes many molecules at once. Showing that one specific molecule causes a benefit needs an experiment that blocks it — something that is easy in mice and rare in people. The interleukin-6 trial below is one of the few human examples.
Interleukin-6 Was the First Signal Traced to Working Human Muscle
Interleukin-6 (IL-6) is described in the research as a key regulator of immune function. Its role in exercise is a different one, and it is the best-documented exerkine in people.
In people — muscle releases it. In a 2000 study, six healthy men straightened one knee over and over against a light load for five hours (25 watts, 40% of their peak power) while researchers sampled blood going into and coming out of both legs. Interleukin-6 in arterial blood rose 19-fold compared with rest. The working leg released interleukin-6 into the blood; the resting leg did not release a significant amount. The amount released by the muscle over the last two hours was 17-fold higher than the rise seen in the blood, which the authors read as a very fast turnover. They suggested that interleukin-6 from contracting muscle helps keep blood sugar steady during long exercise.
In people — it moves fat. In a 2003 study, 18 healthy men received a three-hour infusion of either salt water or one of two doses of lab-made human interleukin-6. Both doses raised fatty acids in the blood, and these levels reached about 50% above the salt-water group by the end of the infusion and stayed raised for at least three hours afterwards. Whole-body fat burning rose after the second hour. At the low dose the change happened without any change in adrenaline, insulin or glucagon, and the authors observed no adverse side effects.
In people — blocking it changed the result of exercise. This is the strongest human test of any exerkine. In a 2019 randomized, placebo-controlled trial, adults with abdominal obesity were given either tocilizumab (a drug that blocks the interleukin-6 receptor) or a placebo during a 12-week program of either bicycle exercise or no exercise. Exercise reduced visceral fat (the fat around the organs), but this effect was abolished when interleukin-6 was blocked. Lean body mass did not differ between groups. The trial also found that blocking interleukin-6 raised cholesterol levels, and exercise did not reverse that. The authors conclude that interleukin-6 is required for exercise to reduce visceral fat in this setting. More about the drug itself is on the tocilizumab page.
The same molecule rising during exercise and during infection can be confusing. The records above describe short, sharp pulses from working muscle; they do not address long-term raised interleukin-6 in chronic disease, which is a separate topic covered on the inflammatory markers page.
Irisin Became Famous Before It Could Be Measured
Irisin is the exerkine most often named in popular articles, and its story is a useful warning about how fast a mouse finding can outrun the human evidence.
2012 — the discovery (mice). A study in Nature reported that a muscle protein called fibronectin type III domain-containing protein 5 is cut and released into the blood as a new hormone, which the authors named irisin. In mice, irisin acted on white fat cells, in dishes and in living animals, to switch on a brown-fat-like (heat-producing) program. Mildly raising irisin in the blood increased energy use in mice without changes in movement or food intake, and improved obesity and blood sugar control. The paper also stated that irisin is induced with exercise in mice and in humans.
2013 — a genetic doubt (human genes and cells). A team analysing the gene found that in rodents and most primates it starts with the usual “start” signal, but in humans that signal carries a mutation (ATG changed to ATA). Human cells given the human version of the gene made only 1% of the full-length protein made from the usual start signal. In muscle samples from two human exercise studies, the gene's activity was not changed by endurance or strength training, and human fat-precursor cells did not turn “brite” (brown-like) when given irisin. The authors judged it “rather unlikely” that the effects seen in mice would carry over to humans.
2014–2015 — a measurement problem. A 2014 review noted that different studies using different commercial antibody test kits reported human irisin levels over a wide range, and that human cell models showed no browning of the main white fat stores. In 2015, a group tested the antibodies inside four commercial kits and found that they reacted strongly with other, unrelated proteins in human and animal blood. They concluded that their results “call into question all previous data obtained with commercial ELISA kits for irisin” and titled the paper “Irisin — a myth rather than an exercise-inducible myokine.”
2015 — mass spectrometry (people). The original discovery group then measured irisin with mass spectrometry, a method that identifies molecules by their exact weight, using heavy-isotope reference peptides as internal standards. They reported that human irisin is made mainly from the unusual ATA start signal and circulates at about 3.6 nanograms per millilitre in sedentary people and about 4.3 nanograms per millilitre in people doing aerobic interval training. Their conclusion: human irisin exists, circulates and is regulated by exercise.
Since then — mixed human results. In a 2023 study that measured 16 exerkines in young sedentary adults before and after exercise, irisin was among the molecules that were “not modified or not detectable”.
Where that leaves irisin: by mass spectrometry it is real and present in human blood at low levels, and the difference measured between sedentary and training people was small (about 3.6 versus 4.3 nanograms per millilitre). Many older human studies that used antibody kits are hard to interpret. The brown fat animation on this site shows the heat-making process irisin was proposed to drive.
Beta-Aminoisobutyric Acid Rises a Little in People and Acts Strongly in Mice
Beta-aminoisobutyric acid (BAIBA) is a small amino-acid-like molecule, not a protein, which is why later papers call it an exerkine or “metabokine” rather than a myokine. Its full story — the two mirror-image forms, the gene that sets each person's level, and the supplement trials — is on the BAIBA page. In brief:
- Cells and mice (2014). Muscle cells forced to make extra amounts of a master switch for exercise genes released beta-aminoisobutyric acid. It turned on brown-fat genes in white fat cells and fat burning in liver cells, in dishes and in mice, pushed human stem cells in a dish toward a brown-fat-like type, and improved blood sugar control in mice. In people, the same paper reports that blood levels rose with exercise and were inversely linked to metabolic risk factors — an association, not a test of cause.
- People (2019). In 15 healthy, recreationally active adults who cycled for an hour at 40% of their peak power, the two forms of beta-aminoisobutyric acid rose by 13% and 20%. One form was 67 times more plentiful in the blood than the other (1,734 versus 29.3 nanomoles per litre at rest).
- People (2023). In the 2023 study of 16 exerkines, beta-aminoisobutyric acid was not modified by a maximal walking test or a resistance session.
- Mice, human muscle cells and people (2026). A study in mice found that the L-form drives most of its effects on muscle; in human muscle cells grown in a dish it changed markers of muscle-fibre type; and in people, blood L-form levels tracked aerobic fitness and rose with endurance training.
The only outcome trial of beta-aminoisobutyric acid as a supplement in people found no effect on body composition or metabolism (see the section on pills below).
Lactate Is a Fuel and a Signal, Not Just Waste
Lactate (often called lactic acid) was long thought of as a waste product of exercise without enough oxygen. A 2018 review of “lactate shuttle” research states that lactate is formed continuously even when oxygen is plentiful, and that moving between the cells that make it and the cells that use it, it serves at least three purposes: a major energy source, the main raw material the body uses to make new glucose, and a signalling molecule. The review adds that some clinicians now see raised blood lactate as a sign of “strain” rather than “stress”, and that clinical studies are using lactate to treat inflammatory conditions and to fuel working muscles in sports medicine. The lactate and Cori cycle animation shows how lactate moves between muscle and liver, and the lactate lab test page covers what blood levels mean in hospital medicine.
- In people. In the 2023 study of 16 exerkines, lactate rose in the blood three minutes after both a maximal walking test and a resistance session. The rise in lactate after exercise was positively associated with the volume, glucose uptake and density of the volunteers' brown fat — an association.
- In mice. A 2019 study in male mice found that lactate released by muscle during exercise crosses the blood–brain barrier and switches on brain-derived neurotrophic factor (a growth factor for nerve cells) in the hippocampus, the brain's memory centre. Lactate-driven increases in this growth factor went with better spatial learning and memory in the mice. The authors called lactate a component of the “exercise pill”; that phrase describes a mouse finding.
Fibroblast Growth Factor 21 Comes From the Liver
Fibroblast growth factor 21 (FGF21) is a hormone that rises in the blood after exercise, and studies of exerkines include it in their lists. A 2016 human study points to the liver as its source during exercise, which makes it a hepatokine.
- In people — hormones from the pancreas drive it. Young healthy men cycled for two hours. The ratio of glucagon to insulin (two blood-sugar hormones from the pancreas) rose 10-fold during exercise. When researchers held those hormones steady with a “pancreatic clamp”, the exercise-induced rise in fibroblast growth factor 21 was completely blunted, and the rise in another hepatokine, follistatin, was about halved.
- In people with type 2 diabetes. In the same study, the rise in fibroblast growth factor 21 after one hour of cycling was completely absent in patients with type 2 diabetes, and the rise in follistatin was impaired. The paper also notes that resting levels of both are higher in type 2 diabetes.
- In people — timing. In the 2023 study of 16 exerkines, fibroblast growth factor 21 rose 30 and 60 minutes after a maximal walking test.
Fibroblast growth factor 21 is also the exerkine that has gone furthest as a medicine, in the form of an engineered long-acting version of the protein (see the section on pills). Other pages on this site discuss it in the context of methionine restriction.
Apelin, Meteorin-Like and Osteocalcin Are Newer Candidates
Apelin
A 2018 study reported that apelin, a small peptide, is produced in response to muscle contraction, and that its production falls with age in both humans and rodents.
- In people. Apelin was positively associated with the benefits of exercise in older persons — an association.
- In mice. Mice lacking apelin or its receptor developed marked problems with muscle function as they aged. Restoring apelin signalling in old mice improved muscle function, by building new mitochondria (the cell's power units), clearing damaged cell parts, calming inflammation and helping muscle stem cells repair tissue.
The authors proposed apelin as a possible early marker of age-related muscle loss (sarcopenia) and a target for future drugs. No human treatment trial appears in the record. Muscle loss with age is covered on the creatine and sarcopenia page.
Meteorin-Like
Meteorin-like was identified in 2014 as a circulating factor made in muscle after exercise and in fat after cold exposure.
- In mice. Raising its blood level increased energy use, improved glucose tolerance and switched on beige-fat (heat-producing) and anti-inflammatory genes. It worked through immune cells inside fat (eosinophils and macrophages), and blocking it reduced the fat's response to long cold exposure.
- In people — it can rise. In 20 young men, plasma meteorin-like rose after a downhill run designed to damage muscle, along with the number of eosinophils in the blood.
- In people — it does not always rise. In the 2023 study of 16 exerkines, meteorin-like was not modified or not detectable after exercise.
- In people — the opposite direction from the mouse idea. Among 800 adults, meteorin-like levels were higher in the 400 with type 2 diabetes than in the 400 without (median 1,219.9 versus 1,131.2 picograms per millilitre), and people in the highest third of levels had an odds ratio of 3.53 for diabetes compared with the lowest third. A hormone that improves blood sugar in mice was, in people, more common in those with diabetes. A cross-sectional study cannot say why.
Osteocalcin
Osteocalcin is a protein made by bone-building cells. One form of it, called undercarboxylated osteocalcin, acts as a hormone. Its activation depends on vitamin K, which is why it appears on the vitamin K and insulin sensitivity page.
- Mainly in mice. A 2016 study reports that circulating levels of the active form double during aerobic exercise, and that levels fall early in adulthood in mice, monkeys and humans. In mice, osteocalcin signalling in muscle fibres was needed for muscle to take up and burn glucose and fat during exercise, and it accounted for most of the interleukin-6 released by exercising mouse muscle. Giving osteocalcin raised the exercise capacity of young mice and gave 15-month-old mice the exercise capacity of 3-month-old mice. This is a bone-to-muscle signal, the reverse of the usual direction.
- In people. In 43 healthy young men who did one session of high-intensity interval cycling (eight two-minute bouts at 85% of maximal power), undercarboxylated osteocalcin was higher after exercise in all three genetic groups studied.
What the Records Report for Blood Sugar, Fat, Bone and Brain
Blood sugar
In people, interleukin-6 from working muscle was proposed to help hold blood sugar steady during long exercise, and the hormones that control blood sugar (glucagon and insulin) drive the exercise rise in fibroblast growth factor 21. In mice, beta-aminoisobutyric acid, irisin, meteorin-like and osteocalcin each improved blood sugar control or glucose use. In people, the human links for beta-aminoisobutyric acid and meteorin-like are associations, and for meteorin-like the association runs the opposite way. See the insulin resistance section for approaches tested in people.
Fat tissue and “browning”
Turning white fat into heat-burning beige fat was the headline claim for irisin, beta-aminoisobutyric acid and meteorin-like — all shown in mice or in cells. Human fat-precursor cells did not brown when given irisin in the 2013 study. The clearest human result about fat is a different one: blocking interleukin-6 cancelled the loss of visceral fat that exercise produced over 12 weeks. Cold exposure is the other common trigger studied for brown fat.
Bone and muscle
Bone talks back to muscle through osteocalcin (mostly mouse evidence, with a human rise after interval cycling). Apelin's role in ageing muscle comes from mice, with human associations. The bone-cell findings for beta-aminoisobutyric acid, also mostly in mice, are on the BAIBA page.
Brain
All the direct brain evidence is from animals:
- Irisin (mice, 2013). Endurance exercise raised irisin's parent protein in the mouse hippocampus, and raising irisin in the blood by delivering the gene to the liver switched on brain-derived neurotrophic factor and other protective genes in the hippocampus.
- Irisin (Alzheimer's disease tissue and mice, 2019). Irisin and its parent protein were reduced in the hippocampus and spinal fluid in Alzheimer's disease, and in experimental models of it. In Alzheimer's model mice, raising irisin rescued memory and the strengthening of connections between nerve cells, and blocking it weakened the protective effect of exercise on memory.
- Lactate (male mice, 2019). As above, lactate crossed into the brain and raised brain-derived neurotrophic factor, with better learning and memory.
In people, the 2023 study of 16 exerkines found brain-derived neurotrophic factor in the blood rose three minutes after a maximal walking test. That is a blood measurement, not a brain one. The brain aging page covers what has been tested on memory and thinking in people.
Most Findings Come From Mice, and Human Data Often Differ
Nearly every exerkine on this page was discovered and given its job description in mice. The human records repeatedly show a weaker or different picture, for several reasons that appear in the studies themselves:
- The genes can differ. The human version of the irisin gene carries an unusual start signal that, in human cells, produced only 1% of the full-length protein.
- The tools can fail. The irisin antibody kits used in many early human studies reacted with other proteins, so their numbers may not have measured irisin at all.
- The size of the change differs. In people, beta-aminoisobutyric acid rose by 13–20% after an hour of cycling; irisin measured by mass spectrometry was about 4.3 rather than 3.6 nanograms per millilitre in people doing interval training. Many of the mouse effects came from raising levels deliberately — giving the molecule itself or delivering extra copies of its gene.
- The source can differ. Fibroblast growth factor 21 rises after exercise in people, but the pancreatic-clamp study traced the rise to blood-sugar hormones acting on the liver, not to muscle.
- Many signals did not move in people. In the 2023 study, which tested 16 exerkines in 10 young sedentary adults, then measured the responsive ones in 28 more, adiponectin, atrial natriuretic peptide, beta-aminoisobutyric acid, meteorin-like, follistatin, pro-atrial natriuretic peptide, irisin and myostatin were not modified or not detectable. A low-volume resistance session raised only lactate. A 24-week training program in 110 people did not change resting levels of any of them.
- Associations can point the wrong way. Meteorin-like improved blood sugar in mice but was higher in people with type 2 diabetes.
The human evidence that stands out is short-term and specific: muscle does release interleukin-6 while working; interleukin-6 does mobilise fat when infused; and blocking interleukin-6 did remove one effect of 12 weeks of exercise on visceral fat. For most other exerkines, the human record is measurements in the blood and associations.
Exerkines as Pills: What Trials Have Tested
If exercise works partly through these signals, an obvious question is whether they can be taken directly. The human trial record is small.
- Beta-aminoisobutyric acid — null. In a 2026 randomized, double-blind trial, 37 adults with overweight or obesity followed a calorie-reduced diet and a weekly exercise program for 56 days and took a placebo (12 people), 500 mg of L-beta-aminoisobutyric acid (13 people), or the same dose combined with 40 mg of grains of paradise, a spice of the ginger family (12 people). There were no differences between groups in body mass, resting metabolic rate, fat mass, fat-free mass, body-fat percentage, resting heart rate, blood pressure, glucose or any blood-lipid measure. The only difference was lower self-rated hunger in the supplement groups.
- Interleukin-6 — short infusions only. Lab-made interleukin-6 infused for three hours raised fat release and fat burning in 18 healthy men. This was a physiology experiment, not a treatment trial. The one longer human trial went the other way: it blocked interleukin-6 with tocilizumab, and that cancelled the visceral-fat loss from exercise.
- Fibroblast growth factor 21 — as an experimental drug for fatty liver disease. Efruxifermin is an engineered, long-acting version of fibroblast growth factor 21. In a phase 2b trial, 31 adults with type 2 diabetes and metabolic dysfunction-associated steatohepatitis (fatty liver disease with inflammation; these patients also had liver scarring) who were already taking a glucagon-like peptide-1 receptor agonist received efruxifermin 50 mg (21 people) or placebo (10 people) once a week for 12 weeks. Liver fat fell by 65% with efruxifermin versus 10% with placebo. The most frequent side effects were mild to moderate stomach and bowel symptoms; one patient stopped because of nausea. This tests a drug modelled on an exercise-linked hormone in a disease setting; it is not a test of an exercise substitute.
- Irisin, meteorin-like, apelin and osteocalcin — no human treatment trials in these records. Their effects as treatments come from mice. The apelin authors describe it as a target for a future “pharmacological strategy”.
- Lactate. The 2018 review mentions clinical studies using lactate for inflammatory conditions and sports medicine; it does not present lactate as a substitute for exercise.
None of the records read for this page shows a pill or injection reproducing the overall effects of exercise in people. The phrase “exercise pill” appears in a mouse study of lactate, not in a human trial. For the questions supplement labels raise, see BAIBA, which sets out the full human record of a product sold on exerkine claims.
What Is Not Known
- Which signals matter most in people. The 2022 review states that the mechanisms behind exercise's benefits remain poorly understood. Only interleukin-6 has been blocked in a human exercise trial.
- How much irisin changes with exercise in people, and whether the small differences measured by mass spectrometry do anything in human tissues.
- Why some human studies find a rise and others do not — for example, meteorin-like rose after muscle-damaging downhill running but not after a walking test or resistance session in another study.
- Whether regular training changes resting levels. A 24-week program in 110 people did not change resting levels of the exerkines that were tested; in that study, the changes appeared minutes to an hour after a single session.
- Whether the brain findings apply to people. The irisin and lactate brain results are from mice; the human evidence is lower irisin in Alzheimer's disease tissue and a brief rise of brain-derived neurotrophic factor in the blood.
- Whether any exerkine given as a supplement has a lasting effect in people. The one supplement outcome trial (beta-aminoisobutyric acid) was null for every body measurement over 56 days.
- What happens in older people and people with chronic disease. Apelin falls with age, the fibroblast growth factor 21 response was absent in type 2 diabetes, and osteocalcin falls early in adulthood. Apart from the efruxifermin trial in type 2 diabetes with fatty liver disease, the records read for this page contain no treatment trials in these groups.
Exercise itself has a much larger body of human evidence than any single exerkine; that evidence is summarised on the Exercise page.
Key Research Papers
- Chow LS, Gerszten RE, Taylor JM, et al. Exerkines in health, resilience and disease. Nat Rev Endocrinol. 2022;18(5):273-289. PubMed PMID: 35304603
- Steensberg A, van Hall G, Osada T, et al. Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6. J Physiol. 2000;529 Pt 1(Pt 1):237-42. PubMed PMID: 11080265
- van Hall G, Steensberg A, Sacchetti M, et al. Interleukin-6 stimulates lipolysis and fat oxidation in humans. J Clin Endocrinol Metab. 2003;88(7):3005-10. PubMed PMID: 12843134
- Wedell-Neergaard AS, Lang Lehrskov L, Christensen RH, et al. Exercise-Induced Changes in Visceral Adipose Tissue Mass Are Regulated by IL-6 Signaling: A Randomized Controlled Trial. Cell Metab. 2019;29(4):844-855.e3. PubMed PMID: 30595477
- Boström P, Wu J, Jedrychowski MP, et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481(7382):463-8. PubMed PMID: 22237023
- Raschke S, Elsen M, Gassenhuber H, et al. Evidence against a beneficial effect of irisin in humans. PLoS One. 2013;8(9):e73680. PubMed PMID: 24040023
- Elsen M, Raschke S, Eckel J. Browning of white fat: does irisin play a role in humans? J Endocrinol. 2014;222(1):R25-38. PubMed PMID: 24781257
- Albrecht E, Norheim F, Thiede B, et al. Irisin - a myth rather than an exercise-inducible myokine. Sci Rep. 2015;5:8889. PubMed PMID: 25749243
- Jedrychowski MP, Wrann CD, Paulo JA, et al. Detection and Quantitation of Circulating Human Irisin by Tandem Mass Spectrometry. Cell Metab. 2015;22(4):734-740. PubMed PMID: 26278051
- Mendez-Gutierrez A, Aguilera CM, Osuna-Prieto FJ, et al. Exercise-induced changes on exerkines that might influence brown adipose tissue metabolism in young sedentary adults. Eur J Sport Sci. 2023;23(4):625-636. PubMed PMID: 35152857
- Roberts LD, Boström P, O'Sullivan JF, et al. β-Aminoisobutyric acid induces browning of white fat and hepatic β-oxidation and is inversely correlated with cardiometabolic risk factors. Cell Metab. 2014;19(1):96-108. PubMed PMID: 24411942
- Stautemas J, Van Kuilenburg ABP, Stroomer L, et al. Acute Aerobic Exercise Leads to Increased Plasma Levels of R- and S-β-Aminoisobutyric Acid in Humans. Front Physiol. 2019;10:1240. PubMed PMID: 31611815
- Daou HN, Watt NT, Gad SA, et al. The metabokine β-aminoisobutyric acid mediates exercise performance and skeletal muscle adaptation through a PGC1α-BAIBA-PPARδ axis. Nat Commun. 2026;17(1):8090. PubMed PMID: 42613329
- Allen LE, Sutton PJ, Schrautemeier A, et al. Effects of L-BAIBA supplementation with and without grains of paradise on changes in resting metabolic rate, body composition, and cardiometabolic risk factors. Nutr J. 2026;25(1):92. PubMed PMID: 42271377
- Brooks GA. The Science and Translation of Lactate Shuttle Theory. Cell Metab. 2018;27(4):757-785. PubMed PMID: 29617642
- El Hayek L, Khalifeh M, Zibara V, et al. Lactate Mediates the Effects of Exercise on Learning and Memory through SIRT1-Dependent Activation of Hippocampal Brain-Derived Neurotrophic Factor (BDNF). J Neurosci. 2019;39(13):2369-2382. PubMed PMID: 30692222
- Hansen JS, Pedersen BK, Xu G, et al. Exercise-Induced Secretion of FGF21 and Follistatin Are Blocked by Pancreatic Clamp and Impaired in Type 2 Diabetes. J Clin Endocrinol Metab. 2016;101(7):2816-25. PubMed PMID: 27163358
- Harrison SA, Frias JP, Lucas KJ, et al. Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study. Clin Gastroenterol Hepatol. 2025;23(1):103-113. PubMed PMID: 38447814
- Vinel C, Lukjanenko L, Batut A, et al. The exerkine apelin reverses age-associated sarcopenia. Nat Med. 2018;24(9):1360-1371. PubMed PMID: 30061698
- Rao RR, Long JZ, White JP, et al. Meteorin-like is a hormone that regulates immune-adipose interactions to increase beige fat thermogenesis. Cell. 2014;157(6):1279-1291. PubMed PMID: 24906147
- Alizadeh A, Alizadeh H. Downhill running exercise increases circulating level of myokine meteorin-like hormone in humans. J Sports Med Phys Fitness. 2022;62(5):700-704. PubMed PMID: 34313414
- Chung HS, Hwang SY, Choi JH, et al. Implications of circulating Meteorin-like (Metrnl) level in human subjects with type 2 diabetes. Diabetes Res Clin Pract. 2018;136:100-107. PubMed PMID: 29199003
- Mera P, Laue K, Ferron M, et al. Osteocalcin Signaling in Myofibers Is Necessary and Sufficient for Optimum Adaptation to Exercise. Cell Metab. 2016;23(6):1078-1092. PubMed PMID: 27304508
- Levinger I, Yan X, Bishop D, et al. The influence of α-actinin-3 deficiency on bone remodelling markers in young men. Bone. 2017;98:26-30. PubMed PMID: 28254467
- Wrann CD, White JP, Salogiannnis J, et al. Exercise induces hippocampal BDNF through a PGC-1α/FNDC5 pathway. Cell Metab. 2013;18(5):649-59. PubMed PMID: 24120943
- Lourenco MV, Frozza RL, de Freitas GB, et al. Exercise-linked FNDC5/irisin rescues synaptic plasticity and memory defects in Alzheimer's models. Nat Med. 2019;25(1):165-175. PubMed PMID: 30617325
PubMed Topic Searches
Connections
- Mind, Body and Lifestyle — the category this page belongs to
- Exercise — the human evidence for exercise itself
- BAIBA (Beta-Aminoisobutyric Acid) — one exerkine in full, including its supplement trials
- Tocilizumab — the interleukin-6 blocker used in the visceral-fat trial
- Brown Fat: How You Burn Calories as Heat — the process irisin was proposed to drive
- Lactate and the Cori Cycle — how lactate moves between muscle and liver
- Vitamin K2, Osteocalcin, and Insulin Sensitivity — the bone hormone and vitamin K
- Insulin Resistance — the blood-sugar problem several exerkines are studied for
- Brain Aging — what has been tested on memory in people